Signs and symptoms associated with the transfusion of WBC‐reduced RBCs and non‐WBC‐reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study

Lane, Thomas A.; Gernsheimer, Terry; Mohandas, Kala; Assmann, Susan F.

doi:10.1046/j.1537-2995.2002.00036.x

Cited by 7 publications

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Simancas‐Racines

Osorio

Martí‐Carvajal³

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundA blood transfusion is an acute intervention, implemented to solve life and health-threatening conditions on a short-term basis. However, blood transfusions have adverse events, some of them potentially related to immune modulation or to a direct transmission of infectious agents (e.g. cytomegalovirus). Leukoreduction is a process in which the white blood cells are intentionally reduced in packed red blood cells (PRBCs) in order to reduce the risk of adverse reactions. The potential benefits of leukoreduced PRBCs in all types of transfused patients for decreasing infectious and non-infectious complications remain unclear. ObjectivesTo determine the clinical effectiveness of leukoreduction of packed red blood cells for preventing adverse reactions following allogeneic blood transfusion. Search methodsWe ran the most recent search on 10th November 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE (OvidSP), Embase(OvidSP), CINAHL Plus (EBSCO), LILACS (BIREME), and clinical trials registers. In addition, we checked the reference lists of all relevant trials and reviews identified in the literature searches. Selection criteriaRandomised clinical trials including patients of all ages requiring PRBC allogeneic transfusion. Any study was eligible for inclusion, regardless of the length of participant follow-up or country where the study was performed. The primary outcome was transfusion-related acute lung injury (TRALI). Secondary outcomes were death from any cause, infection from any cause, non-infectious complications and any other adverse event.1 Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion (Review)

show abstract